PLAQUE PSORIASIS

This study tests an experimental drug called ORKA-001 in 80 adults with moderate-to-severe plaque psoriasis. Participants receive either ORKA-001 or a placebo injection, and doctors measure how much skin clears up after 16 weeks. The goal is to see if ORKA-001 is safe and effecti…

This phase 3 study tests an oral drug called JNJ-77242113 in 311 adults with plaque psoriasis affecting special areas like the scalp, genitals, or palms and soles. Participants receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug clears or nearly…

This phase 3 trial tests an oral drug called JNJ-77242113 in 774 adults with moderate to severe plaque psoriasis. Participants receive either the new drug, a placebo, or an active comparator (deucravacitinib) to see how well it clears skin lesions. The main goal is to measure imp…

This phase 3 trial tests a new cream (MC2-01) containing two active ingredients for plaque psoriasis in Chinese adults. About 537 participants will use either the new cream, a standard gel, or a placebo cream for 8 weeks. The main goal is to see if the new cream clears skin bette…

This phase 3 study tests an experimental oral drug, JNJ-77242113, in about 731 adults with moderate to severe plaque psoriasis. Participants receive either the new drug, a placebo, or an active comparator (deucravacitinib) to see how well it clears skin lesions. The main goal is …

This study is checking the long-term safety and effectiveness of the drug ESK-001 (envudeucitinib) for people with plaque psoriasis. It includes 165 adults who have already completed a previous ESK-001 study. Participants will take the drug as an oral tablet and be monitored for …

This phase 3 trial tests an oral drug called JNJ-77242113 for people with moderate to severe plaque psoriasis. About 684 participants will receive either the drug or a placebo to see if it improves skin clearance. The study also includes a withdrawal and retreatment phase to chec…

This study tests a new cream called HSK44459 in healthy volunteers and people with plaque psoriasis. The first part checks safety and how the body processes the cream. The second part looks at whether different strengths of the cream can improve psoriasis symptoms over 8 weeks. A…

This Phase 3 trial tests an oral drug called JNJ-77242113 in 752 adults with moderate to severe plaque psoriasis. Participants receive either the new drug, a placebo, or an active comparator (Stelara). The study measures how well the drug clears skin lesions at 16 weeks. The goal…

This study is checking the long-term safety and side effects of an experimental pill called TAK-279 in about 2,100 adults with moderate-to-severe plaque psoriasis. All participants will take the drug for up to 4 years, with regular clinic visits. The goal is to see how well peopl…

This phase 3 trial tests the drug netakimab in children aged 6 and older with moderate to severe plaque psoriasis. The study compares netakimab to a placebo and also includes an open-label group receiving adalimumab. The main goal is to see if netakimab improves skin symptoms, me…

This study tests a cream called tapinarof for children aged 2 to 17 with plaque psoriasis, a skin condition causing red, scaly patches. The cream is applied once daily to see if it is safe and tolerable. About 58 children will take part in this open-label trial, meaning everyone …

This study looks at how well the drug deucravacitinib works for adults with moderate plaque psoriasis in real-life clinics across China. Researchers will track skin clearance and symptom improvement in 153 people who are just starting the medication. The goal is to see if results…

This study looks at the long-term safety and effectiveness of the drug ESK-001 for people with moderate to severe plaque psoriasis. Participants are adults who have already completed a prior ESK-001 study. They will take ESK-001 twice daily for 24 weeks, and some may later switch…

This study tests a new medicine called picankibart for people with plaque psoriasis who did not improve enough after using standard IL-17 antibody treatments. About 308 adults in China will take part. The goal is to see if switching to picankibart can clear or nearly clear the sk…

This phase 3 trial tests whether CT-P55, a biosimilar of secukinumab, works as well as the approved drug Cosentyx for moderate to severe plaque psoriasis. 153 adults with chronic psoriasis for at least 6 months are receiving either CT-P55 or Cosentyx injections. The main goal is …

This phase 3 trial is testing whether apremilast (Otezla) can safely and effectively treat moderate to severe plaque psoriasis in Japanese children and adolescents aged 6 to 17. The study involves 17 participants who take oral tablets for 16 weeks. The main goal is to see if thei…

This study follows 550 adults with moderate-to-severe plaque psoriasis who are starting deucravacitinib in routine German clinics. Over 5 years, researchers will measure how well the drug clears skin and improves quality of life. The goal is to see how the treatment works outside…

This study is testing the safety of the drug apremilast (Otezla) in 51 children and teens aged 6 to 17 with mild to moderate plaque psoriasis. Participants take the drug as an oral tablet, and researchers monitor for side effects, growth, and development. The goal is to see if th…

This study tests whether a daily pill called IRX4204 can safely improve mild to moderate plaque psoriasis in adults. Twenty participants will take the drug or a placebo for 28 days and have weekly checkups. The goal is to see if the drug clears or nearly clears skin plaques and i…

This study uses an iPhone app to track symptoms of psoriasis and psoriatic arthritis in 1,000 adults. Participants complete surveys, take photos of their skin, and use phone sensors to measure joint function. The goal is to see if smartphones can reliably monitor these conditions…